SB 950 requires health care service plans and health insurers in California to cover all medically necessary treatments or medications that the FDA approves for Alzheimer’s disease or related dementias for contracts and policies issued, amended, or renewed on or after January 1, 2027. The bill bars step therapy requirements for those FDA‑approved treatments in nearly all circumstances and instructs plans to treat nonself‑administered (physician‑administered) FDA‑approved dementia therapies as outpatient prescription drug benefits.
The measure aims to expand patient access to newly approved dementia drugs while limiting formulary sequencing that can delay treatment. It creates operational and cost implications for insurers, pharmacy and infusion networks, and providers, and it carves out specific policy and Medi‑Cal exceptions while requiring an “expeditious” authorization pathway for prescribers.
At a Glance
What It Does
For plans/policies issued, amended, or renewed on or after Jan 1, 2027, the bill requires coverage of medically necessary, FDA‑approved Alzheimer’s/dementia treatments; prohibits step therapy as a prerequisite for those treatments (with a narrow exception); and mandates that physician‑administered FDA‑approved dementia treatments covered as a medical benefit also be available as an outpatient prescription drug benefit.
Who It Affects
State‑regulated health care service plans (Knox‑Keene) and health insurers writing policies in California, prescribing providers for dementia therapies, infusion centers and specialty pharmacies, and patients diagnosed with Alzheimer’s or related dementias. The bill does not apply to certain limited benefit plans or specified Medi‑Cal managed care contracts.
Why It Matters
SB 950 removes a common utilization management barrier (step therapy) for an emerging class of high‑cost dementia drugs and forces benefit‑design changes that affect where and how physician‑administered treatments are billed and reimbursed. That creates immediate operational work for plans and providers and long‑term cost exposure for payers and purchasers.
More articles like this one.
A weekly email with all the latest developments on this topic.
What This Bill Actually Does
SB 950 adds parallel provisions to the Health and Safety Code (for Knox‑Keene plans) and the Insurance Code (for insurers). The core requirement is straightforward: if the FDA approves a drug or treatment for Alzheimer’s disease or related dementias, a California‑regulated plan or policy issued, amended, or renewed on or after January 1, 2027, must cover that treatment when a provider determines it is medically necessary.
The statute expressly contemplates treatments that slow or reduce clinical decline.
The bill prohibits step therapy protocols as a precondition to coverage of FDA‑approved dementia treatments for both self‑administered and physician‑administered drugs, subject to a limited exception: if the FDA has approved multiple types of treatment, the plan need not drop step therapy for all treatments provided that at least one antiamyloid therapy is covered without step therapy. Besides the step therapy restriction, plans may still use usual utilization management tools, such as prior authorization, provided those determinations mirror how the plan treats medical necessity for other covered conditions.A notable operational requirement forces parity between medical‑benefit and pharmacy‑benefit handling: when a plan covers a nonself‑administered, FDA‑approved dementia treatment as a medical benefit (for example, an infusion), the plan must also include that treatment as an outpatient prescription drug benefit.
To support access, the bill requires plans and insurers to maintain an expeditious authorization process by which prescribing providers can obtain approval for medically necessary, FDA‑approved dementia treatments. The law also caps coverage criteria: plans cannot make coverage requirements more restrictive than the FDA‑approved indications.The statute lists exclusions and exceptions: it does not apply to vision‑only, dental‑only, certain limited benefit policies, or to specified Medi‑Cal managed care contracts; Medicare supplement and some specialized plans are also exempt.
Finally, the bill’s legislative materials note fiscal and enforcement implications tied to willful violations and local‑agency costs, though the operative text focuses on coverage, step therapy, benefit classification, authorization processes, and exclusions.
The Five Things You Need to Know
Effective date and scope: Applies to health care service plan contracts and health insurance policies issued, amended, or renewed on or after January 1, 2027.
Step therapy ban with narrow carveout: Prohibits step therapy for both self‑administered and physician‑administered FDA‑approved dementia treatments, unless the plan covers at least one antiamyloid therapy without step therapy and then may apply step therapy to other types.
Outpatient prescription benefit requirement: If a plan covers a nonself‑administered FDA‑approved dementia treatment as a medical benefit, the plan must also offer it as an outpatient prescription drug benefit.
Coverage‑criteria parity with FDA labeling: Plans may not impose coverage criteria that are more restrictive than the FDA‑approved indications for the treatment.
Specified exclusions: The law excludes dental‑only, vision‑only, certain limited policies, Medicare supplement, and specified Medi‑Cal managed care contracts from its requirements.
Section-by-Section Breakdown
Every bill we cover gets an analysis of its key sections.
Coverage mandate for Knox‑Keene plans
This subdivision imposes an affirmative coverage duty on health care service plan contracts issued, amended, or renewed on or after Jan 1, 2027: plans must cover all medically necessary FDA‑approved treatments for Alzheimer’s and related dementias as determined by the treating provider. The provision expressly includes treatments that reduce clinical decline, which signals legislative intent to cover disease‑modifying therapies in addition to symptomatic treatments.
Step therapy prohibition, utilization management, and FDA‑label parity
These paragraphs define and prohibit step therapy protocols for FDA‑approved dementia treatments for both oral/self‑administered and physician‑administered drugs, while carving out a narrow exception tied to antiamyloid therapies. At the same time, the text preserves standard utilization management tools, such as prior authorization, but insists those determinations be made the same way the plan treats other conditions. Finally, it forbids coverage criteria that are stricter than the FDA’s approved indications, limiting plans’ ability to create narrower clinical eligibility.
Treatment‑type parity and expedited authorization process
The bill requires plans that cover nonself‑administered, FDA‑approved dementia treatments as a medical benefit to also list those treatments as outpatient prescription drug benefits, which affects billing, network participation, and pharmacy reimbursement flows. It also mandates that plans maintain an expeditious authorization pathway for prescribers—an operational standard with little statutory specificity, leaving implementation details to regulators and plan procedures.
Statutory exclusions
The statute excludes certain narrow‑benefit contracts—dental‑only, vision‑only, Medicare supplement, and specified Medi‑Cal managed care contracts—from the new coverage requirements. For insurers, the exclusions also list accident‑only, specified disease, and hospital indemnity policies. These carveouts limit the bill’s reach to mainstream medical and pharmacy benefits under state‑regulated plans and policies.
Parallel requirements for health insurers
This section mirrors the Health and Safety Code requirements for health insurers writing policies in California: coverage mandate, step therapy prohibition with the same exception, utilization‑management parity, outpatient prescription benefit requirement, and the expeditious authorization process. The duplication creates symmetry between DMHC‑regulated plans and DOI‑regulated insurers but leaves federal ERISA‑governed self‑insured plans outside the state law’s direct reach.
Fiscal and enforcement framing
The bill includes the standard Section 6/Article XIII B reimbursement exclusion language stating no state reimbursement is required for local agencies because the costs arise from criminal‑penalty related changes. Legislative counsel’s digest and fiscal notes reference willful violations by health care service plans as criminal under existing law and flag local costs, but the added statutory text focuses on coverage duties and administrative obligations rather than prescribing new monetary penalties within the new sections themselves.
This bill is one of many.
Codify tracks hundreds of bills on Healthcare across all five countries.
Explore Healthcare in Codify Search →Who Benefits and Who Bears the Cost
Every bill creates winners and losers. Here's who stands to gain and who bears the cost.
Who Benefits
- Patients with Alzheimer’s disease or related dementias — gain faster access to FDA‑approved therapies without being forced through stepwise medication trials, and clearer parity between infusion/clinic‑based therapies and outpatient pharmacy coverage.
- Prescribing neurologists, geriatricians, and primary care providers — get a statutory basis to request FDA‑approved dementia treatments as medically necessary and access an 'expeditious' authorization route intended to shorten delays.
- Infusion centers and specialty pharmacies — potential increase in referrals and demand because plans must offer physician‑administered treatments as outpatient prescription benefits, expanding billing and dispensing channels.
- Manufacturers of FDA‑approved dementia therapies — increased market access and reduced coverage barriers, particularly for novel antiamyloid agents.
- Caregivers and family members — potential earlier initiation of disease‑modifying treatments that may slow decline, changing care planning and resource needs.
Who Bears the Cost
- California‑regulated health insurers and Knox‑Keene health care service plans — face higher utilization risk from covering high‑cost dementia therapies without step therapy, and administrative costs to change formularies and authorization processes.
- Employers and purchasers of fully insured plans — may see upward pressure on premiums passed through by insurers to cover increased drug and treatment spending.
- Pharmacies, infusion clinics, and provider billing departments — must rework billing protocols, contract terms, and reconciliation processes when treatments shift between medical and outpatient prescription benefit structures.
- State regulators (DMHC and Department of Insurance) — will need to interpret 'expeditious' authorization standards, monitor compliance, and potentially resolve disputes about FDA‑label vs. plan coverage rules, creating workload and oversight costs.
- Patients on ERISA self‑insured employer plans — indirectly affected but not covered by the law; disparity in coverage between fully insured and self‑insured populations could shift care patterns and pressure employers to change plan designs.
Key Issues
The Core Tension
The bill pits faster access to high‑cost, potentially disease‑modifying dementia therapies against payers’ need to manage uncertain clinical benefit and large budget impacts: expand access now and risk sharp premium increases and network disruption, or allow utilization controls that delay some patients’ access while payers limit exposure and gather real‑world evidence.
SB 950 addresses an urgent access problem but leaves several implementation questions unresolved. The statute requires an 'expeditious' authorization process and forbids coverage criteria more restrictive than FDA indications, yet it does not define timelines, metrics, or process standards for what counts as expeditious.
Regulators will need to translate that phrase into enforceable rules or guidance, or disputes between providers and plans will proliferate.
The outpatient prescription benefit requirement forces plans to reconcile differing networks, billing codes, and reimbursement pathways (medical benefit vs. pharmacy benefit). That change can improve patient access by allowing pharmacy dispensing of some therapies, but it also raises questions about site‑of‑care discounts, buy‑and‑bill reimbursement models, and who pays for administration services.
Plans and providers will need to renegotiate contracts and may encounter gaps in reimbursement that slow, rather than speed, patient access.
On costs and clinical uncertainty, the bill tightly restricts step therapy but preserves prior authorization. Removing sequencing requirements for many high‑cost dementia drugs increases utilization risk at a time when clinical benefits and eligible populations are still being clarified.
The statutory exception that allows step therapy so long as at least one antiamyloid therapy is available without step therapy creates a tactical path for payers to centralize access around a single product while still imposing sequencing on others—potentially encouraging formulary gaming rather than broad access.
Try it yourself.
Ask a question in plain English, or pick a topic below. Results in seconds.